Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide.
BACKGROUND
Leflunomide, an inhibitor of protein kinase activity and pyrimidine synthesis, is an experimental immunosuppressive agent effective in the prevention/control of acute and chronic rejection in animal models and currently in phase I clinical trials in human transplant recipients. This agent is also effective in the control of graft-versus-host disease, autoimmune reactions, and the growth of certain tumors. The importance of the endothelium in these disease processes led us to hypothesize that leflunomide might act directly upon the endothelial cell (EC).


RESULTS
Assay of human EC colony formation demonstrated dose-dependent, leflunomide-mediated inhibition of EC proliferation. In addition, the organization of EC into capillary-like networks, which occurs during 18 hr of incubation on Matrigel, was progressively disrupted with increasing concentrations of leflunomide. Finally, fibrin-embedded transverse sections of murine aorta, which sprout numerous microvessels during an 11-day incubation, were inhibited from doing so in the presence of this agent. All drug concentrations used in these experiments were nontoxic and pharmacologically relevant, and none of these effects were reversible by exogenous uridine, implying that inhibition of these processes was not due to intracellular pyrimidine depletion. Furthermore, neither cyclosporine nor tacrolimus exerted inhibitory activity in any of the experiments described above.


CONCLUSIONS
Data generated by these studies distinguish leflunomide among immunosuppressants as uniquely capable of inhibiting angiogenesis-related endothelial functions and suggest additional mechanisms by which this agent might intervene in the diverse array of disease processes against which it has shown therapeutic potential.
Waldman
W J
WJ
Department of Pathology, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA. waldman.1@osu.edu
Bickerstaff
A
A
Gordillo
G
G
Orosz
K
K
Knight
D A
DA
Orosz
C G
CG
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D003470:Culture Media; D016572:Cyclosporine / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D000077339:Leflunomide; D051379:Mice; D008833:Microcirculation / Q000187:drug effects / Q000502:physiology; D023421:Models, Animal; D016559:Tacrolimus / Q000494:pharmacology; D014471:Umbilical Veins; D014529:Uridine / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D003470:Culture Media; D007555:Isoxazoles; D016572:Cyclosporine; D000077339:Leflunomide; D014529:Uridine; D016559:Tacrolimus